NEW YORK, May 17, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed on behalf of those who purchased shares of NewLink Genetics Corporation ("NewLink" or the "Company") (NASDAQ: NLNK) between September 17, 2013 and May 9, 2016 inclusive (the "Class Period").
NewLink is a biopharmaceutical company that focuses on developing immunotherapeutic products, namely algenpantucel-L, to enhance treatment options for patients with cancer.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts regarding NewLink's business and operations and specifically failed to disclose that: (1) algenpantucel-L was ineffective and possibly harmful to patients; and (2) consequentially, NewLink's public statements were materially false and misleading at all relevant times.
On Monday, May 9, 2016, NewLink's phase III study disclosed that its experimental cancer vaccine, known as algenpantucel-L, which was designed to stimulate a patient's immune system to recognize and kill cancer cells, did not actually do so and failed to prolong survival in patients with pancreatic cancer compared to a standard therapy. Following this news, NewLink stock dropped to $5.05 per share, or 30.61%, to close at $11.45 on May 10, 2016.
No Class has yet been certified in the above action. If you wish to review a copy of the Complaint or join the action, please visit the firm's site: http://www.bgandg.com/#!nlnk/omiv7. To discuss this action, or for any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in NewLink you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-newlink-genetics-corporation-nlnk-and-lead-plaintiff-deadline-july-11-2016-300269382.html
SOURCE Bronstein, Gewirtz & Grossman, LLC